Loading news...
Shares of LivaNova PLC (NASDAQ: LIVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on
Emerald Advisers LLC raised its stake in LivaNova PLC (NASDAQ: LIVN) by 2.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 551,162 shares of the company's stock after purchasing an additional 12,163 shares during the quarter. Emerald Advisers LLC
Campbell and CO Investment Adviser LLC acquired a new position in shares of LivaNova PLC (NASDAQ: LIVN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,227 shares of the company's stock, valued at approximately $798,000. Several other large investors have
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LivaNova PLC (NASDAQ: LIVN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w.
LivaNova PLC (NASDAQ: LIVN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The
Sintx Technologies (NASDAQ: SINT - Get Free Report) and LivaNova (NASDAQ: LIVN - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Institutional and Insider Ownership 18.4% of Sintx Technologies shares
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. “At the heart of LivaNova's purpose as a Comp.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. “Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector,” Makatsaria said. “With her extensive OSA.
Envestnet Asset Management Inc. trimmed its stake in shares of LivaNova PLC (NASDAQ: LIVN) by 78.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,118 shares of the company's stock after selling 36,715 shares during the period. Envestnet
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible.
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Classification (APC) 1580 for new patient implants (NPIs) under the 2026 Medicare Hospital Outpatient Prospective Payment System.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. “We are confident in our ability to deliver on the targets we outlined today. LivaNova's talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our.
LivaNova PLC ( LIVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Financial Officer Ahmet Tezel - Chief Innovation Officer Conference Call Participants Michael Polark - Wolfe Research, LLC Adam Maeder - Piper Sandler & Co., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Americas LLC David Rescott - Robert W. Baird & Co. Incorporated, Research Division Michael Matson - Needham & Company, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to LivaNova plc Third Quarter 2025 Earnings Conference Call.
LivaNova (LIVN) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.9 per share a year ago.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an organic basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.49 and adjusted dilut.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Wolfe Research Healthcare Conference 2025 in New York City. The presentation will take place Mon., Nov. 17, at 2:40 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register t.
LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and raised guidance, driven by Cardiopulmonary and Neuromodulation segment performance. Despite a 20% short-term return, I see further upside due to robust fundamentals, market expansion, and clinical milestones supporting the investment thesis.